Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.

The Journal of antimicrobial chemotherapy - 1 Aug 2015

Reigadas E, Alcalá L, Marín M, Pelaéz T, Martin A, Iglesias C, Bouza E

Abstract excerpt

OBJECTIVES: Clostridium difficile infection (CDI) is the leading cause of hospital-acquired diarrhoea in developed countries. Metronidazole and vancomycin are the mainstay of treatment, although they are associated with treatment failure and recurrence. Novel agents have emerged to address these shortcomings. We investigated the in vitro activity of a novel agent, surotomycin (formerly CB-183,315), and seven...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Infective Agents
Share to Clostridioides difficile

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clostridium Infections

Share to Lipopeptides

Share to Microbial Sensitivity Tests

Share to Peptides, Cyclic

Share to Ribotyping

Source

Identifiers

PMID: 25876881
DOI: 10.1093/jac/dkv092

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain.PMID 25876881Read ↗

Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species.Semantic proximity Read ↗

Antimicrobial susceptibility and virulence gene analysis of Clostridioides difficile from healthcare-associated infections in Southern Brazil.Semantic proximity Read ↗

Effects of surotomycin on Clostridium difficile viability and toxin production in vitro.Semantic proximity Read ↗

Clostridioides difficile infections were predominantly driven by fluoroquinolone-resistant Clostridioides difficile ribotypes 176 and 001 in Slovakia in 2018–2019Semantic proximity Read ↗

Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes.Semantic proximity Read ↗

Reference Susceptibility Testing and Genomic Surveillance ofClostridioides difficile, United States, 2012–17Semantic proximity Read ↗

Mode of Action and Bactericidal Properties of Surotomycin against Growing and Nongrowing Clostridium difficileSemantic proximity Read ↗

Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators.Semantic proximity Read ↗

In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin.Semantic proximity Read ↗

<i>In Vitro</i> Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of <i>Staphylococcus</i> spp. and <i>Enterococcus</i> sppSemantic proximity Read ↗

In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.Semantic proximity Read ↗

Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficileSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.